Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTBP2 | P56545 | 9/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 3/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.38 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.38 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 3/20 | 0.37 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL559315 | 1.00 | CTBP2 (0.57) | CTBP2BLMESR1ESR2HDAC3 | |
| SCHEMBL559795 | 0.88 | CTBP2 (0.54) | CTBP2CYP1A2CYP2C19 | |
| SCHEMBL559796 | 0.88 | CTBP2 (0.54) | CTBP2CYP1A2CYP2C19 | |
| Eucomic Acid SCHEMBL12466852 | 0.80 | BLM (0.51) | BLMESR1ESR2CYP1A2CA2 | |
| Eucomic Acid SCHEMBL23355983 | 0.80 | BLM (0.51) | BLMESR1ESR2CYP1A2CA2 | |
| SCHEMBL5343038 | 0.74 | BLM (0.56) | CTBP2BLMESR1ESR2CA2 | |
| SCHEMBL11282868 | 0.73 | CTBP2 (1.00) | CTBP2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL11282864 | 0.73 | CTBP2 (1.00) | CTBP2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL10088121 | 0.71 | BLM (0.53) | BLMESR1ESR2CYP2C19CA2 | |
| SCHEMBL27594847 | 0.70 | BLM (0.47) | CTBP2BLMESR1ESR2CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101450907-B | Processes for the preparation of glutamic acid compounds intermediates and novel intermediates used in the processes | AJINOMOTO KK | 2013-07-17 | — | — | CN | disclosed |
| US-20120035373-A1 | PROCESSES OF PRODUCING GLUTAMIC ACID COMPOUNDS AND PRODUCTION INTERMEDIATES THEREFORE AND NOVEL INTERMEDIATE FOR THE PROCESSES | AJINOMOTO CO. INC (JP) | 2012-02-09 | — | — | US | disclosed |
| US-7868187-B2 | Processes of producing glutamic acid compounds and production intermediates therefore and novel intermediate for the processes | AJINOMOTO CO., INC. (JP) | 2011-01-11 | — | — | US | disclosed |
| US-20100105924-A1 | PROCESSES OF PRODUCING GLUTAMIC ACID COMPOUNDS AND PRODUCTION INTERMEDIATES THEREFORE AND NOVEL INTERMEDIATE FOR THE PROCESSES | AJINOMOTO CO. INC. (JP) | 2010-04-29 | — | — | US | disclosed |
| US-7678925-B2 | Processes of producing glutamic acid compounds and production intermediates therefore and novel intermediate for the processes | AJINOMOTO CO., INC. (JP) | 2010-03-16 | — | — | US | disclosed |
| US-20090259052-A1 | PROCESSES OF PRODUCING GLUTAMIC ACID COMPOUNDS AND PRODUCTION INTERMEDIATES THEREFORE AND NOVEL INTERMEDIATE FOR THE PROCESSES | AJINOMOTO CO. INC (JP) | 2009-10-15 | — | — | US | disclosed |
| CN-101450907-A | Processes for the preparation of glutamic acid compounds and intermediates thereof and novel intermediates used in the processes | AJINOMOTO KK (JP) | 2009-06-10 | — | — | CN | disclosed |
| CN-100465156-C | Process for producing glutamic acid compound and intermediate for producing the same, and novel intermediate for use therein | AJINOMOTO KK (JP) | 2009-03-04 | — | — | CN | disclosed |
| US-7390909-B2 | Processes of producing glutamic acid compounds and production intermediates therefore and novel intermediate for the processes | AJINOMOTO CO., INC. (JP) | 2008-06-24 | — | — | US | disclosed |
| US-20080091032-A1 | PROCESSES OF PRODUCING GLUTAMIC ACID COMPOUNDS AND PRODUCTION INTERMEDIATES THEREFORE AND NOVEL INTERMEDIATE FOR THE PROCESSES | AJINOMOTO CO. INC (JP) | 2008-04-17 | — | — | US | disclosed |
| US-7064219-B2 | Processes of producing glutamic acid compounds and production intermediates therefore and novel intermediate for the processes | AJINOMOTO CO., INC. (JP) | 2006-06-20 | — | — | US | disclosed |
| US-20060074249-A1 | Processes of producing glutamic acid compounds and production intermediates therefore and novel intermediate for the processes | AJINOMOTO CO. INC (JP) | 2006-04-06 | — | — | US | disclosed |
| CN-1610658-A | Process for producing glutamic acid compound and intermediate for producing the same, and novel intermediate for use therein | AJINOMOTO KK (JP) | 2005-04-27 | — | — | CN | disclosed |
| US-20050004394-A1 | Processes of producing glutamic acid compounds and production intermediates therefore and novel intermediate for the processes | AJINOMOTO CO. IN (JP) | 2005-01-06 | — | — | US | disclosed |
| EP-1466890-A1 | PROCESSES FOR THE PREPARATION OF GLUTAMIC ACID COMPOUNDS AND INTERMEDIATES THEREOF AND NOVEL INTERMEDIATES USED IN THE PROCESSES | Ajinomoto Co., Inc. (JP) | 2004-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035373-A1 | PROCESSES OF PRODUCING GLUTAMIC ACID COMPOUNDS AND PRODUCTION INTERMEDIATES THEREFORE AND NOVEL INTERMEDIATE FOR THE PROCESSES | GLUL, MON2, GRIK5 | CTBP2 2823/4885BLM 4326/4885ESR1 4033/4885 |
| US-20050004394-A1 | Processes of producing glutamic acid compounds and production intermediates therefore and novel intermediate for the processes | GLUL, MON2, GRIK5 | CTBP2 2823/4885BLM 4326/4885ESR1 4033/4885 |
| US-20080091032-A1 | PROCESSES OF PRODUCING GLUTAMIC ACID COMPOUNDS AND PRODUCTION INTERMEDIATES THEREFORE AND NOVEL INTERMEDIATE FOR THE PROCESSES | GLUL, MON2, GRIK5 | CTBP2 2823/4885BLM 4326/4885ESR1 4033/4885 |
| US-20100105924-A1 | PROCESSES OF PRODUCING GLUTAMIC ACID COMPOUNDS AND PRODUCTION INTERMEDIATES THEREFORE AND NOVEL INTERMEDIATE FOR THE PROCESSES | GLUL, MON2, GRIK5 | CTBP2 2823/4885BLM 4326/4885ESR1 4033/4885 |
| US-20060074249-A1 | Processes of producing glutamic acid compounds and production intermediates therefore and novel intermediate for the processes | GLUL, MON2, GRIK5 | CTBP2 2823/4885BLM 4326/4885ESR1 4033/4885 |
| US-20090259052-A1 | PROCESSES OF PRODUCING GLUTAMIC ACID COMPOUNDS AND PRODUCTION INTERMEDIATES THEREFORE AND NOVEL INTERMEDIATE FOR THE PROCESSES | GLUL, MON2, GRIK5 | CTBP2 2823/4885BLM 4326/4885ESR1 4033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.